NCT00851136

A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer (APM4566g)

A Phase Ib Study of the Safety and Pharmacokinetics of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 9 (actual)
• Sponsor: Genentech, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This will be a multicenter, open-label study enrolling a total of up to 23 patients.

Conditions

• Metastatic Colorectal Cancer

Interventions

Type	Name	Description
DRUG	bevacizumab	Intravenous repeating dose
DRUG	FOLFOX	Intravenous repeating dose
DRUG	PRO95780	Intravenous repeating dose

Timeline

• Start date: 2009-05-01
• Primary completion: 2010-06-01
• Completion: 2010-06-01
• First posted: 2009-02-25
• Last updated: 2022-12-13